Medivir: Regulatory tailwind from the FDA in OI

AI SummaryClose X

DNB Carnegie published a flash comment highlighting a regulatory tailwind from the FDA in OI; the RNS itself contained no revenue, profit/loss, cash or debt figures, no guidance, and no operational metrics or management statements, and directs investors to the full DNB Carnegie report for details, so material impact is suggested by the FDA-related wording but not quantified in this announcement.

Disclaimer*

Companies

Medivir AB (0GP7)
UK 100